{"id":6403,"date":"2019-11-15T22:25:33","date_gmt":"2019-11-15T16:55:33","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=6403"},"modified":"2025-05-08T12:12:38","modified_gmt":"2025-05-08T06:42:38","slug":"chronic-obstructive-pulmonary-disease-treatment-market","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/chronic-obstructive-pulmonary-disease-treatment-market","title":{"rendered":"\ufeffIs Air Pollution a driver in COPD Treatment Market?"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a0a517676af8\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a0a517676af8\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/chronic-obstructive-pulmonary-disease-treatment-market\/#Death_rates_due_to_Air_pollution\" >Death rates due to Air pollution<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/chronic-obstructive-pulmonary-disease-treatment-market\/#Chronic_Obstructive_Pulmonary_Disease_Epidemiology\" >Chronic Obstructive Pulmonary Disease Epidemiology<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/chronic-obstructive-pulmonary-disease-treatment-market\/#Chronic_Obstructive_Pulmonary_Disease_Treatment\" >Chronic Obstructive Pulmonary Disease Treatment<\/a><ul class='ez-toc-list-level-4' ><li class='ez-toc-heading-level-4'><ul class='ez-toc-list-level-4' ><li class='ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/chronic-obstructive-pulmonary-disease-treatment-market\/#Bronchodilator\" >Bronchodilator<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/chronic-obstructive-pulmonary-disease-treatment-market\/#Corticosteroid\" >Corticosteroid<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/chronic-obstructive-pulmonary-disease-treatment-market\/#Oxygen_therapy\" >Oxygen therapy<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/chronic-obstructive-pulmonary-disease-treatment-market\/#Companies_advancing_Chronic_Obstructive_Pulmonary_Disease_treatment_market\" >Companies advancing Chronic Obstructive Pulmonary Disease treatment\nmarket<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.delveinsight.com\/blog\/chronic-obstructive-pulmonary-disease-treatment-market\/#Chronic_Obstructive_Pulmonary_Disease_Pipeline\" >Chronic Obstructive Pulmonary Disease Pipeline<\/a><ul class='ez-toc-list-level-4' ><li class='ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.delveinsight.com\/blog\/chronic-obstructive-pulmonary-disease-treatment-market\/#MV130\" >MV130<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/www.delveinsight.com\/blog\/chronic-obstructive-pulmonary-disease-treatment-market\/#Dupilumab\" >Dupilumab<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/www.delveinsight.com\/blog\/chronic-obstructive-pulmonary-disease-treatment-market\/#Abediterol\" >Abediterol<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/www.delveinsight.com\/blog\/chronic-obstructive-pulmonary-disease-treatment-market\/#DS102\" >DS102<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/www.delveinsight.com\/blog\/chronic-obstructive-pulmonary-disease-treatment-market\/#PUL-042\" >PUL-042<\/a><\/li><\/ul><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n\n<p class=\"has-drop-cap\">Levels of air pollution have risen dramatically over the past years due to increasing outdoor human activities such as industrialization, urbanization and indoor activities like burning of solid fuels, coal, etc. <br>This has contaminated the air we breathe with several harmful substances such as Sulfur dioxide (SO2), Nitrogen oxides (NOx), Ozone (O3), particulate matters, Carbon monoxide (CO) and other volatile organic compounds. <\/p>\n\n\n\n<p>For years, air pollution has been recognized as one of the gravest concerns for humans as, along with leading to respiratory problems, it also leads to cardiovascular diseases. The year 2017, as observed by the State of Global Air, saw that Air pollution was ranked the fifth position behind the leading mortality rates. Moreover, around 4.9 million deaths have been caused due to the polluted air costing people 147 million years of life. <\/p>\n\n\n\n<p>According to estimates by the WHO, around 7 million deaths were caused due to exposure to fine particles in the air that penetrate deep into lungs causing cardiovascular and lung disease. <\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Death_rates_due_to_Air_pollution\"><\/span><strong>Death rates due to Air pollution <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<div class=\"wp-block-image is-resized\"><figure class=\"aligncenter is-resized\"><img decoding=\"async\" src=\"https:\/\/i0.wp.com\/www.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/Untitled-3.jpg?fit=800%2C2000&amp;ssl=1\" alt=\"Deaths due to Air pollution\" class=\"wp-image-6456\" width=\"400\" height=\"1000\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/Untitled-3.jpg 800w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/Untitled-3-120x300.jpg 120w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/Untitled-3-768x1920.jpg 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/Untitled-3-410x1024.jpg 410w\" sizes=\"(max-width: 400px) 100vw, 400px\" \/><figcaption><a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-obstructive-pulmonary-disease-copd-epidemiology-forecast\">Deaths due to Air pollution<\/a><\/figcaption><\/figure><\/div>\n\n\n\n<p>Chronic Obstructive Pulmonary Disease (COPD) is a progressive chronic\nrespiratory disease that affects the breathing process hampering the in-and-out\nof the air from the lungs.&nbsp; <\/p>\n\n\n\n<p>Excess accumulation of the mucus in the airway passage, inflammation of\nthe lungs, or the narrowing of the lungs contribute to COPD. <\/p>\n\n\n\n<p class=\"has-text-color has-background has-very-light-gray-color has-very-dark-gray-background-color\">COPD is usually prevalent in individuals who smoke.<\/p>\n\n\n\n<div class=\"wp-block-image\"><figure class=\"aligncenter\"><img decoding=\"async\" width=\"2230\" height=\"1392\" src=\"https:\/\/i1.wp.com\/www.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/Stop-Smoking.png?fit=2230%2C1392&amp;ssl=1\" alt=\"COPD prevalence in Smokers\" class=\"wp-image-6405\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/19062931\/Stop-Smoking.png 2230w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/19062931\/Stop-Smoking-300x187.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/19062931\/Stop-Smoking-1024x639.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/19062931\/Stop-Smoking-1536x959.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/19062931\/Stop-Smoking-2048x1278.png 2048w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/19062931\/Stop-Smoking-772x482.png 772w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/19062931\/Stop-Smoking-20x12.png 20w\" sizes=\"(max-width: 2230px) 100vw, 2230px\" \/><figcaption>Smoking is a leading cause of COPD.<\/figcaption><\/figure><\/div>\n\n\n\n<p>However, this does not mean that non-smokers are completely shielded from developing the disease. The quality air we breathe affects the chances of developing Chronic Obstructive Pulmonary Disease. Intake of harmful fumes, dust particles, and other genetic factors also are contributing factors that leave the lungs vulnerable.  <\/p>\n\n\n\n<p>COPD can be categorized into two main types: Chronic Bronchitis and Emphysema. Chronic Bronchitis involves the chronic inflammation of the airways leading to the thickened lining of the airways. On the other hand, in the case of Emphysema the walls of alveolar sacs shatter hampering the process of gas exchange in the lungs.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Chronic_Obstructive_Pulmonary_Disease_Epidemiology\"><\/span><strong>Chronic Obstructive Pulmonary Disease Epidemiology<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p style=\"background-color:#cddfee\" class=\"has-background\">Chronic Obstructive Pulmonary Disease prevalence worldwide as estimated by a study was observed to be around over 65 Million people. Moreover, the number is predicted to increase in the coming next 50 years. <\/p>\n\n\n\n<p><strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-obstructive-pulmonary-disease-copd-epidemiology-forecast\">Chronic Obstructive Pulmonary Disease prevalence<\/a><\/strong> increases with increasing age.<\/p>\n\n\n\n<p>As per the World Health Organization estimates, in the United States, Chronic Obstructive Pulmonary Disease is the third leading cause of death. Looking at the figures provided by the CDC, around 11.8 Million adults age 18 and above were suffering from COPD during 2007 and 2009. <\/p>\n\n\n\n<p>The trend in the UK is equally saddening. As per the British Lung Foundation, one in five people develop asthma, COPD or any other form of respiratory disorder. <\/p>\n\n\n\n<p>Recent trends showed an increase in the number of deaths due to Chronic Obstructive Pulmonary Disease estimated to be around 3 Million in the year 2015. By 2030, the number is expected to rise. Moreover, the WHO predicts that Chronic Obstructive Pulmonary Disease would be the fourth most prevalent cause of death by 2030. <\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Chronic_Obstructive_Pulmonary_Disease_Treatment\"><\/span><strong>Chronic Obstructive Pulmonary Disease Treatment <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The goal of Chronic Obstructive Pulmonary Disease treatment is to add quality to the lives of COPD patient pool. Improving lung function, helping in easing symptoms, and preventing the recurrence of exacerbations is the main aim of Chronic Obstructive Pulmonary Disease therapy. <\/p>\n\n\n\n<p>At present, there exists no standard cure for Chronic Obstructive Pulmonary Disease treatment. However, there exist therapies that can slow down the progression of the disease and help in controlling the symptoms. <\/p>\n\n\n\n<p>The emphasis of the COPD therapeutics outlook is on changing the lifestyle of the patients, such as stop smoking. This is the only voluntary activity that can be adopted by the patient to stop COPD from getting worse. <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Bronchodilator\"><\/span><strong>Bronchodilator<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>To help relieve the symptoms, there exist many therapeutics options such as Bronchodilators. They are the only effective Chronic Obstructive Pulmonary Disease therapy options which helps in reliving coughing and reducing shortening of breath while relaxing the muscles. The severity of the disease decides the administration of the short-acting bronchodilator, long-acting bronchodilator or both. <\/p>\n\n\n\n<p>Inhaled long-acting \u03b22 agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) are some of the most commonly used bronchodilators with an aim to improve the airflow and reduce the air trapping. <\/p>\n\n\n\n<p>Some of the regulatory-approved bronchodilators for Chronic Obstructive Pulmonary Disease treatment are <strong>Incruse<\/strong> <strong>Ellipta<\/strong> (GlaxoSmithKline), <strong>Tudorza Pressair <\/strong>(Forest Laboratories), and <strong>Yupelri<\/strong> (Theravance Biopharma). <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Corticosteroid\"><\/span><strong>Corticosteroid<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>In a similar manner, to reduce the airway inflammation, and prevent exacerbations, Inhaled corticosteroid medications are also used. Fluticasone and budesonide are the two such examples of inhaled steroids which are used in Chronic Obstructive Pulmonary Disease treatment market. <\/p>\n\n\n\n<p>Interestingly, combination therapy of bronchodilators and inhaled steroids,\nsuch as Salmeterol and fluticasone and formoterol and budesonide have proven to\nbe efficient in COPD management. <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Oxygen_therapy\"><\/span><strong>Oxygen therapy<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>Long-term oxygen<a> <\/a>therapy<a> <\/a>is prescribed to patients with severe resting or moderate hypoxemia. In extreme cases, Lung transplantation remains the only viable COPD option which can help in decreasing mortality rates and increasing quality of life. <\/p>\n\n\n\n<p>The current Chronic Obstructive Pulmonary Disease treatment market only comprises of only a few approved therapies. It is expected that the launch of merging COPD therapies will contribute to the overall growth of the market during the forecast period of 2019\u20132028.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Companies_advancing_Chronic_Obstructive_Pulmonary_Disease_treatment_market\"><\/span><strong>Companies advancing Chronic Obstructive Pulmonary Disease treatment\nmarket<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Major Chronic Obstructive Pulmonary Disease players such as <strong>Afimmune<\/strong>, <strong>Inmunotek S.L<\/strong>., <strong>Sanofi<\/strong>, <strong>AstraZeneca<\/strong>, and <strong>Pulmotect, Inc<\/strong>. are involved in establishing their foothold in the COPD treatment market. <\/p>\n\n\n\n<figure class=\"wp-block-image\"><img decoding=\"async\" width=\"1956\" height=\"1270\" src=\"https:\/\/i2.wp.com\/www.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/Chronic-Obstructive-Pulmonary-Disease-Comapnies.jpg?fit=1956%2C1270&amp;ssl=1\" alt=\"Chronic Obstructive Pulmonary Disease Companies\" class=\"wp-image-6408\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/21215822\/Chronic-Obstructive-Pulmonary-Disease-Comapnies.jpg 1956w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/21215822\/Chronic-Obstructive-Pulmonary-Disease-Comapnies-300x195.jpg 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/21215822\/Chronic-Obstructive-Pulmonary-Disease-Comapnies-1024x665.jpg 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/21215822\/Chronic-Obstructive-Pulmonary-Disease-Comapnies-768x499.jpg 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/21215822\/Chronic-Obstructive-Pulmonary-Disease-Comapnies-1536x997.jpg 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/21215822\/Chronic-Obstructive-Pulmonary-Disease-Comapnies-20x13.jpg 20w\" sizes=\"(max-width: 1956px) 100vw, 1956px\" \/><figcaption> <br><a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-obstructive-pulmonary-disease-copd-epidemiology-forecast\"><strong>Chronic Obstructive Pulmonary Disease<\/strong> <strong>Companies<\/strong><\/a><\/figcaption><\/figure>\n\n\n\n<p>The expected launch of therapies by the companies mentioned above and many more players in the COPD market, without a second thought, are anticipated to change the treatment landscape of in the coming years, as forecasted by DelveInsight. <\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Chronic_Obstructive_Pulmonary_Disease_Pipeline\"><\/span><strong>Chronic Obstructive Pulmonary Disease Pipeline <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"MV130\"><\/span><strong>MV130<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p><strong>MV130<\/strong>, under Phase III trials by <strong>Inmunotek\nS.L<\/strong>, is a bacterial mucosal vaccine in a spray that is administered\nsublingually for treating recurrent respiratory tract infections in both\nchildren and adults. The drug stimulates dendritic cells, thus, modulating the\nfunctional activity of the innate and adaptive immune response. <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Dupilumab\"><\/span><strong>Dupilumab<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p><strong>Dupilumab<\/strong>, is developed by <strong>Sanofi\/Regeneron<\/strong>, is a targeted biologic therapy that inhibits signalling of interleukin-4 (IL-4) and interleukin-13 (IL-13), that are responsible for type 2 inflammation. The therapy is under Phase III stage of development for the patients with COPD type 2 inflammation. If approved, as per DelveInsight forecasts, <strong>Dupilumab <\/strong>dominate the major chunk of the Chronic Obstructive Pulmonary Disease market. <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Abediterol\"><\/span><strong>Abediterol<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p><strong>Abediterol<\/strong> (<strong>AstraZeneca<\/strong>) is a long-acting beta2-agonist (LABA) that has a bronchodilator effect, relaxing the muscles around the airways. It is a novel, once-daily, fine-particle therapy being developed by AstraZeneca for the treatment of chronic obstructive pulmonary disease. This treatment is currently being tested in Phase 2 clinical trials and is a dry powder inhaler (DPI), which consists of a device that delivers the drug directly to the lungs as a very fine powder.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"DS102\"><\/span><strong>DS102<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p><strong>DS102<\/strong> is a drug of <strong>Afimmune<\/strong>, and is\na bioactive lipid with anti-inflammatory, anti-apoptotic, and antifibrotic\neffects. Currently, the drug is in Phase II study for in-chronic obstructive\npulmonary disease (COPD) patients. <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"PUL-042\"><\/span><strong>PUL-042<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p>Another key player <strong>Pulmotect<\/strong>, Inc. is developing a therapy<strong> PUL-042<\/strong> to reduce the exacerbations associated with chronic obstructive pulmonary disease. <\/p>\n\n\n\n<p>Despite several unmet needs such as low diagnosis rates, misdiagnosed cases, and lack of a standard effective permanent cure, increase in awareness and advanced technological and innovative medicines is helping to increase Chronic Obstructive Pulmonary Disease diagnosis. <br>Increasing trends of air pollution, as observed, has led to an increase in the COPD prevalence. This has led to an increased demand for effective COPD therapies to reduce the air passage blockade and improve the breathing. <\/p>\n\n\n\n<p>The launch of effective upcoming therapies will surely steer the Chronic Obstructive Pulmonary Disease market into a positive direction in the future. <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Levels of air pollution have risen dramatically over the past years due to increasing outdoor human activities such as industrialization, urbanization and indoor activities like burning of solid fuels, coal, etc. This has contaminated the air we breathe with several harmful substances such as Sulfur dioxide (SO2), Nitrogen oxides (NOx), Ozone (O3), particulate matters, Carbon [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":6407,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[719,6893,17815,6894,718,903,623],"industry":[17225],"therapeutic_areas":[17243],"class_list":["post-6403","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-chronic-obstructive-pulmonary-disease","tag-chronic-obstructive-pulmonary-disease-market","tag-chronic-obstructive-pulmonary-disease-pipeline","tag-chronic-obstructive-pulmonary-disease-therapy","tag-copd","tag-gsk","tag-who","industry-pharmaceutical","therapeutic_areas-respiratory-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Chronic Obstructive Pulmonary Disease Market Trends | DelveInsight<\/title>\n<meta name=\"description\" content=\"The expected launch of Chronic Obstructive Pulmonary Disease treatment approaches, increased diagnosis and awareness will impact COPD market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/chronic-obstructive-pulmonary-disease-treatment-market\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Chronic Obstructive Pulmonary Disease Market Trends | DelveInsight\" \/>\n<meta property=\"og:description\" content=\"The expected launch of Chronic Obstructive Pulmonary Disease treatment approaches, increased diagnosis and awareness will impact COPD market.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/chronic-obstructive-pulmonary-disease-treatment-market\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-11-15T16:55:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-08T06:42:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/04171318\/Chronic-Obstructive-Pulmonary-Disease-COPD-Treatment-Market.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Chronic Obstructive Pulmonary Disease Market Trends | DelveInsight","description":"The expected launch of Chronic Obstructive Pulmonary Disease treatment approaches, increased diagnosis and awareness will impact COPD market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/chronic-obstructive-pulmonary-disease-treatment-market","og_locale":"en_US","og_type":"article","og_title":"Chronic Obstructive Pulmonary Disease Market Trends | DelveInsight","og_description":"The expected launch of Chronic Obstructive Pulmonary Disease treatment approaches, increased diagnosis and awareness will impact COPD market.","og_url":"https:\/\/www.delveinsight.com\/blog\/chronic-obstructive-pulmonary-disease-treatment-market","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-11-15T16:55:33+00:00","article_modified_time":"2025-05-08T06:42:38+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/04171318\/Chronic-Obstructive-Pulmonary-Disease-COPD-Treatment-Market.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/chronic-obstructive-pulmonary-disease-treatment-market","url":"https:\/\/www.delveinsight.com\/blog\/chronic-obstructive-pulmonary-disease-treatment-market","name":"Chronic Obstructive Pulmonary Disease Market Trends | DelveInsight","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/chronic-obstructive-pulmonary-disease-treatment-market#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/chronic-obstructive-pulmonary-disease-treatment-market#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/04171318\/Chronic-Obstructive-Pulmonary-Disease-COPD-Treatment-Market.jpg","datePublished":"2019-11-15T16:55:33+00:00","dateModified":"2025-05-08T06:42:38+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"The expected launch of Chronic Obstructive Pulmonary Disease treatment approaches, increased diagnosis and awareness will impact COPD market.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/chronic-obstructive-pulmonary-disease-treatment-market"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/chronic-obstructive-pulmonary-disease-treatment-market#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/04171318\/Chronic-Obstructive-Pulmonary-Disease-COPD-Treatment-Market.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/04171318\/Chronic-Obstructive-Pulmonary-Disease-COPD-Treatment-Market.jpg","width":772,"height":482,"caption":"Chronic Obstructive Pulmonary Disease (COPD) Treatment Market"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/11\/04171318\/Chronic-Obstructive-Pulmonary-Disease-COPD-Treatment-Market-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Chronic Obstructive Pulmonary Disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Chronic Obstructive Pulmonary Disease market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Chronic Obstructive Pulmonary Disease Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Chronic Obstructive Pulmonary Disease therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">COPD<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">GSK<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">WHO<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Chronic Obstructive Pulmonary Disease<\/span>","<span class=\"advgb-post-tax-term\">Chronic Obstructive Pulmonary Disease market<\/span>","<span class=\"advgb-post-tax-term\">Chronic Obstructive Pulmonary Disease Pipeline<\/span>","<span class=\"advgb-post-tax-term\">Chronic Obstructive Pulmonary Disease therapy<\/span>","<span class=\"advgb-post-tax-term\">COPD<\/span>","<span class=\"advgb-post-tax-term\">GSK<\/span>","<span class=\"advgb-post-tax-term\">WHO<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Nov 15, 2019","modified":"Updated on May 8, 2025"},"absolute_dates_time":{"created":"Posted on Nov 15, 2019 10:25 pm","modified":"Updated on May 8, 2025 12:12 pm"},"featured_img_caption":"Chronic Obstructive Pulmonary Disease (COPD) Treatment Market","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/6403","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=6403"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/6403\/revisions"}],"predecessor-version":[{"id":31916,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/6403\/revisions\/31916"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/6407"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=6403"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=6403"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=6403"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=6403"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=6403"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}